Company intelligence / Profile preview
Beijing Hanmi Pharmaceutical
- Ownership
- Private
- Development stage
- Commercial
Overview
Beijing Hanmi markets over 20 approved products in China across pediatrics, gastroenterology, orthopedics and anti-infectives. Its pipeline includes next-generation immuno-oncology assets such as BH3120—a bispecific antibody targeting PD-L1 and 4‑1BB—currently in global Phase 1 trials with promising early safety/efficacy data. The company also produces widely used pediatric drugs like Medilac-Vita and Ambroxol Hydrochloride/Clenbuterol Hydrochloride Oral Solution.
- Therapeutic areas
- OncologyPulmonologyEndocrinologyGastroenterology
- Modalities
- Small moleculeMonoclonal antibodyBispecific antibodyProbiotics
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Beijing Hanmi Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Hanmi Pharmaceutical.